134 related articles for article (PubMed ID: 31347926)
1. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Nakamura I; Uno S
Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Nakamura I; Maegawa H; Tobe K; Uno S
Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
[TBL] [Abstract][Full Text] [Related]
5. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Terauchi Y; Yokote K; Nakamura I; Sugamori H
Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Maegawa H; Tobe K; Tabuchi H; Nakamura I
Expert Opin Pharmacother; 2016 Oct; 17(15):1985-94. PubMed ID: 27463414
[TBL] [Abstract][Full Text] [Related]
7. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Nakamura I; Maegawa H; Tobe K; Uno S
Expert Opin Pharmacother; 2021 Feb; 22(3):373-387. PubMed ID: 33012212
[TBL] [Abstract][Full Text] [Related]
8. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Yokote K; Terauchi Y; Nakamura I; Sugamori H
Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
[TBL] [Abstract][Full Text] [Related]
9. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
[TBL] [Abstract][Full Text] [Related]
10. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
12. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Tobe K; Maegawa H; Nakamura I; Uno S
Endocr J; 2021 Aug; 68(8):905-918. PubMed ID: 33827996
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
[TBL] [Abstract][Full Text] [Related]
15. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Tabuchi H; Maegawa H; Tobe K; Nakamura I; Uno S
Endocr J; 2019 Jan; 66(1):31-41. PubMed ID: 30393249
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
Kashiwagi A; Takahashi H; Ishikawa H; Yoshida S; Kazuta K; Utsuno A; Ueyama E
Diabetes Obes Metab; 2015 Feb; 17(2):152-60. PubMed ID: 25347938
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
Kadowaki T; Haneda M; Ito H; Ueno M; Matsukawa M; Yamakura T; Sasaki K; Kimura M; Iijima H
Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
[TBL] [Abstract][Full Text] [Related]
19. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
[TBL] [Abstract][Full Text] [Related]
20. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
